These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16250667)

  • 1. Orally active benzoxazole derivative as 5-HT3 receptor partial agonist for treatment of diarrhea-predominant irritable bowel syndrome.
    Yoshida S; Shiokawa S; Kawano K; Ito T; Murakami H; Suzuki H; Sato Y
    J Med Chem; 2005 Nov; 48(22):7075-9. PubMed ID: 16250667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
    Sato Y; Yamada M; Yoshida S; Soneda T; Ishikawa M; Nizato T; Suzuki K; Konno F
    J Med Chem; 1998 Jul; 41(16):3015-21. PubMed ID: 9685241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
    Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
    J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.
    Yang Z; Fairfax DJ; Maeng JH; Masih L; Usyatinsky A; Hassler C; Isaacson S; Fitzpatrick K; DeOrazio RJ; Chen J; Harding JP; Isherwood M; Dobritsa S; Christensen KL; Wierschke JD; Bliss BI; Peterson LH; Beer CM; Cioffi C; Lynch M; Rennells WM; Richards JJ; Rust T; Khmelnitsky YL; Cohen ML; Manning DD
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6538-41. PubMed ID: 20889341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
    Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Niso M; Perrone R; Tortorella V
    J Med Chem; 2004 Dec; 47(26):6616-24. PubMed ID: 15588097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2-yl)piperazin-1-yl]butyl]quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model.
    Tamaoki S; Yamauchi Y; Nakano Y; Sakano S; Asagarasu A; Sato M
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1315-23. PubMed ID: 17540858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory molecules for the 5-HT3 receptor ion channel gating system.
    Yoshida S; Watanabe T; Sato Y
    Bioorg Med Chem; 2007 May; 15(10):3515-23. PubMed ID: 17391967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
    Manning DD; Cioffi CL; Usyatinsky A; Fitzpatrick K; Masih L; Guo C; Zhang Z; Choo SH; Sikkander MI; Ryan KN; Naginskaya J; Hassler C; Dobritsa S; Wierschke JD; Earley WG; Butler AS; Brady CA; Barnes NM; Cohen ML; Guzzo PR
    Bioorg Med Chem Lett; 2011 Jan; 21(1):58-61. PubMed ID: 21146988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-affinity relationships of 1-[omega-(4-aryl-1-piperazinyl)alkyl]-1-aryl ketones as 5-HT(7) receptor ligands.
    Perrone R; Berardi F; Colabufo NA; Lacivita E; Leopoldo M; Tortorella V
    J Med Chem; 2003 Feb; 46(4):646-9. PubMed ID: 12570387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microwave assisted synthesis of 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists.
    Mahesh R; Perumal RV; Pandi PV
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5179-81. PubMed ID: 15380223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome.
    Zielińska M; Chen C; Mokrowiecka A; Cygankiewicz AI; Zakrzewski PK; Sałaga M; Małecka-Panas E; Wlaź P; Krajewska WM; Fichna J
    J Pharm Pharmacol; 2015 Feb; 67(2):244-54. PubMed ID: 25515402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the pharmacological properties of 5-methoxyindole derivatives at 5-HT4 receptors.
    Coupar IM; Irving HR; Manallack DT; Tan YY; Ayad F; Iulio JD; Tochon-Danguy N; Iskander MN
    J Pharm Pharmacol; 2012 Aug; 64(8):1099-106. PubMed ID: 22775213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
    Leopoldo M; Lacivita E; Contino M; Colabufo NA; Berardi F; Perrone R
    J Med Chem; 2007 Aug; 50(17):4214-21. PubMed ID: 17649988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
    Kawano K; Mori T; Fu L; Ito T; Niisato T; Yoshida S; Shiokawa S; Sato Y; Murakami H; Shishikura T
    Neurogastroenterol Motil; 2005 Apr; 17(2):290-301. PubMed ID: 15787949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    Funatsu T; Takeuchi A; Hirata T; Keto Y; Akuzawa S; Sasamata M
    Eur J Pharmacol; 2007 Nov; 573(1-3):190-5. PubMed ID: 17658508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.
    Sobczak M; Cami-Kobeci G; Sałaga M; Husbands SM; Fichna J
    Eur J Pharmacol; 2014 Aug; 736():63-9. PubMed ID: 24815321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors.
    Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Perrone R; Tortorella V
    J Pharm Pharmacol; 2004 Feb; 56(2):247-55. PubMed ID: 15005884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
    Zou BC; Dong L; Wang Y; Wang SH; Cao MB
    Chin Med J (Engl); 2007 Dec; 120(23):2069-74. PubMed ID: 18167178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.